InsidersTradesSigma
Track the Allogene Therapeutics, Inc. share price and the full management transaction log of the company, a listed equity based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Allogene Therapeutics, Inc. has logged 113 public disclosures. Market capitalisation: €701.3m. The latest transaction was reported on 25 August 2026 (Cession). Among the most active insiders: Bhavnagri Veer. All data is accessible without an account.
113
Insider Decl.
n/a
Thresholds
€2m
3 ops.
Buy Volume
€2m
37 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Allogene Therapeutics, Inc. Strong Buy (bullish), based on 9 analysts. Average price target: US$9.00.
43Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 25 August 2026
Declarations113 total
29,697 shares@ US$2.12Common StockSEC:0001628280-26-058920:0
29,697 shares@ US$2.120.011% mcap39.8% of flowCommon StockSEC144:0001737287-26-000023
2,867 shares@ US$2.5038.3% of flowCommon StockSEC:0002057918-26-000007:0
9,601 shares@ US$1.41100.0% of flowCommon StockSEC:0001835208-25-000007:0
46,668 shares@ US$1.964.3% of flowCommon StockSEC:0001737287-25-000042:0
5,488 shares@ US$1.975100.0% of flowCommon StockSEC:0001737287-25-000040:0
31,755 shares0Common StockSEC:0001737287-25-000026:0
13,313 shares@ US$2.4322.8% of flowCommon StockSEC:0001737287-25-000022:0
46,003 shares@ US$1.683.8% of flowCommon StockSEC:0001737287-25-000017:0
6,404 shares@ US$1.7113.1% of flowCommon StockSEC:0001737287-25-000020:0
4,361 shares@ US$1.730.7% of flowCommon StockSEC:0001737287-25-000019:0
18,832 shares@ US$1.7020.9% of flowCommon StockSEC:0001737287-25-000016:0
14,746 shares@ US$1.7130.3% of flowCommon StockSEC:0001737287-25-000018:0
173,913 shares0Common StockSEC:0001737287-25-000008:0
173,913 shares0Common StockSEC:0001737287-25-000006:0
369,957 shares0Common StockSEC:0001737287-25-000005:0
144,928 shares0Common StockSEC:0001737287-25-000009:0
552,174 shares0Common StockSEC:0001737287-25-000004:0
36,232 shares0Common StockSEC:0001737287-25-000007:0
27,199 shares@ US$1.7831.0% of flowCommon StockSEC:0001737287-25-000003:0
9,136 shares@ US$2.1813.9% of flowCommon StockSEC:0001737287-24-000081:0
9,221 shares@ US$2.1643.9% of flowCommon StockSEC:0001737287-24-000079:0
36,404 shares@ US$2.849.3% of flowCommon StockSEC:0001737287-24-000065:0
28,310 shares@ US$2.78586.9% of flowCommon StockSEC:0001593968-24-001096:0
18,641 shares@ US$2.279329.2% of flowCommon StockSEC:0001593968-24-000878:0
25 of 113 declarations
关于 Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. 是一家总部位于加利福尼亚州南旧金山的美国生物技术公司，在美国纳斯达克市场上市。该公司专注于同种异体 CAR T 细胞疗法，即由供体细胞而非患者自身细胞制成的“现成”细胞疗法。其战略重点主要是肿瘤学，并日益关注自身免疫疾病，这使得 Allogene 置身于现代免疫肿瘤学中最具科学雄心的领域之一。([ir.allogene.com](https://ir.allogene.com/?utm_source=openai)) Allogene 成立于 2017 年，其建立围绕着深厚的细胞疗法和临床开发专业知识。该公司尚未拥有获批的商业产品，仍是一家临床阶段的生物技术公司，这意味着收入生成仍然有限，价值创造在很大程度上取决于临床执行、监管进展及其资产负债表的实力。潜在的投资理由在于标准化同种异体 CAR T 平台是否能克服自体 CAR-T 疗法的一些结构性限制，尤其是在制造时间、物流和可及性方面。([sec.gov](https://www.sec.gov/Archives/edgar/data/1737287/000173728725000051/allo-20241231x10k.pdf?utm_source=openai)) Allogene 的管线以 cema-cel (cemacabtagene ansegedleucel) 和其他几种针对不同血液癌症和自身免疫适应症的同种异体候选产品为中心。该公司的核心论点是，“现成”CAR T 平台可以提供更快的可用性、更可预测的制造，以及可能比患者特异性细胞疗法更具可扩展性的经济效益。从竞争角度来看，Allogene 运营在一个拥挤且高度创新的领域，其中包括大型制药公司和专业的生物技术同行，它们都在追求 CAR-T、工程细胞疗法和下一代免疫学方法。其差异化在于它是同种异体 CAR-T 技术领域中更专注的纯粹开发商之一。([ir.allogene.com](https://ir.allogene.com/?utm_source=openai)) 从地理上看，该业务以美国为中心，尽管该公司正在将其试验活动和合作足迹扩展到其本土市场之外。最近的亮点包括 2026 年 4 月宣布的公开发行股票，将关键的 ALPHA3 试验扩展到韩国和澳大利亚，以及 2026 年管理层将这一年定位为关键转折期的一系列临床和财务更新。对于投资者而言，Allogene 仍然是纳斯达克市场上一家高风险、高回报的开发阶段生物技术公司，其股价表现可能仍然高度受临床数据、现金流和同种异体 CAR-T 路线图执行情况的影响。([ir.allogene.com](https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-announces-pricing-public-offering-common-0?utm_source=openai))
